Using a highly reproducible and robust cell-based high-throughput screening (HTS) assay, the authors screened a 100,000-compound library at 14-and 114-μM compound concentration against influenza strain A/Udorn/72 (H3N2). The "hit" rates (>50% inhibition of the viral cytopathic effect) from the 14-and 114-μM screens were 0.022% and 0.38%, respectively. The hits were evaluated for their antiviral activity, cell toxicity, and selectivity in dose-response experiments. The screen at the lower concentration yielded 3 compounds, which displayed moderate activity (SI 50 = 10-49). Intriguingly, the screen at the higher concentration revealed several additional hits. Two of these hits were highly active with an SI 50 > 50. Time of addition experiments revealed 1 compound that inhibited early and 4 other compounds that inhibited late in the virus life cycle, suggesting they affect entry and replication, respectively. The active compounds represent several different classes of molecules such as carboxanilides, 1-benzoyl-3-arylthioureas, sulfonamides, and benzothiazinones, which have not been previously identified as having antiviral/anti-influenza activity. (Journal of Biomolecular Screening 2008:879-887) 
INTRODUCTION

I
NFLUENZA VIRUSES ARE NEGATIVE-SENSE, single-stranded RNA viruses that infect the upper and lower respiratory tracts and cause substantial morbidity and mortality annually. 1 In the United States, approximately 36,000 deaths are attributed to influenza or its complications each year. [2] [3] [4] Influenza A viruses, which also infect a wide number of avian and mammalian species, pose a considerable public health burden with epidemic and pandemic potential. 5, 6 Approximately 20% to 40% of the world's population became ill during the catastrophic "Spanish" flu pandemic in 1918, which killed 675,000 people in the United States and an estimated 40 to 50 million people worldwide. The "Asian" flu pandemic of 1957 resulted in the deaths of approximately 69,800 people in the United States and 2.0 to 7.4 million worldwide. 7 The current health burden of epidemic influenza, as well as the potential threat of a pandemic, has increased effort toward the discovery and development of antivirals and vaccines for the treatment of influenza disease.
Antiviral drugs for the treatment of influenza target 4 of the 10 influenza virus proteins: hemagglutinin (HA), neuraminidase (NA), M2 ion channel protein (M2), and polymerase (PA). 8 These include oseltamivir (NA), zanamivir (NA), amantadine (M2), rimantadine (HA), and ribavirin (PA). Of these, only oseltamivir and zanamivir were recommended for the treatment of seasonal influenza in 2007-2008 by the Centers for Disease Control and Prevention. 9 Ribavirin 5′-monophosphate resembles guanosine 5′-monophosphate (GMP) and can decrease cellular guanosine 5′-triphosphate (GTP) pools due to the inhibition of the enzyme inosine monophosphate dehydrogenase (IMPDH); however, this decrease does not completely account for the observed antiviral activity for many viruses. Inhibitory effects have also been noted on the capping 10 and translation efficiency 11 of viral mRNA, as well as a direct suppressive effect on the viral polymerase activity in the case of the influenza virus. 10, 12, 13 Remarkably, the most effective antivirals target each of the 3 surface proteins, M2, HA, and NA. M2 acts as an ion channel during the early stages of entry. The 2 other surface proteins, HA and NA, are used to subtype influenza viruses with H1, H2, H3, N1, and N2 associated with human infections. HA binds to host cell sialic acid cell receptors, facilitating penetration of epithelial cells by the virus. NA catalyzes the cleavage of sialic acid residues from glycoproteins, which allows the virus to bud from the plasma membrane unabated and hence aids in virus spread. One drawback of current antivirals is that they must be administered within 48 h of the onset of symptoms to be efficacious. Moreover, oseltamivir and zanamivir are expensive and time-consuming to synthesize. Recently, resistant variants to these drugs have also emerged. Whereas antivirals have played a key role in treatment, vaccines have and will continue to play a dominant role in the prevention of influenza. 8 However, the design of effective influenza vaccines can be hindered by antigenic variation of NA and reassortment of HA and NA genes.
14 Every year, the influenza vaccine contains predicted influenza virus strain variants that have been derived from the surveillance of characterized virus strains from the previous year. Furthermore, in contrast to antivirals, vaccines cannot be developed until a new viral strain emerges. 15, 16 Clearly, the continued emergence of new influenza variants, drug-resistant mutants, and potential pandemic strains demands our attention toward the discovery and development of more effective antiviral therapeutics. High-throughput screening (HTS) offers an important tool in accelerating the discovery of new antiviral leads for new and emerging pathogens such as sudden acute respiratory syndrome (SARS) CoV 17 and pandemic influenza. Toward this, we previously reported the development of a cell-based HTS that monitors virus-induced cytopathic effects (CPEs) in Madin Darby canine kidney (MDCK) cells. 18 Unlike target-oriented approaches, this CPE HTS approach has the advantage that multiple targets can be screened in a single assay against any target involved in viral infection. Confirmatory assays that consist of dose response in an HTS format are easy to perform and provide valuable cytotoxicity data. In addition, lead compounds or unique targets can be identified for structureactivity relationships (SARs). To date, we have screened 1.6 million compounds at BSL-2 and more than 200,000 compounds at BSL3 using this cell-based viability assay for influenza. We have employed this assay to screen 100,000 compounds from ChemBridge at 14 and 114 μM. We report the discovery of 5 hits with anti-influenza activity. Four compounds-ARB-06-003174 (AACF-308027), ARB-06-011087 (AACF-316018), ARB-06-076399 (AACF-381531), and ARB-06-089154 (AACF-394288)-showed inhibition late in the virus lifecycle (6 h postinfection), suggesting they are affecting replication of the virus. Compound ARB-06-018302 (323316) was efficacious early in the virus life cycle (0-3 h postinfection), indicating that it is affecting entry of the virus.
MATERIALS AND METHODS
Cell growth conditions and media
MDCK cells (ATCC CCL-34, American Tissue Culture Type) were maintained as adherent cell lines in Eagle minimum essential medium with 2 mM L-glutamine and 10% fetal bovine serum (FBS) at 37°C in a humidified 5% CO 2 atmosphere as described previously. 18 Cells were passaged as needed and harvested from flasks using 0.25% trypsin-EDTA. HTS validation included establishment of the coefficient of variation (CV) for the MDCK cells to ensure assay quality and read stability. 18 Thus, cells used for the assay were not used past passage 70.
Compound library and controls
The positive control drug for this assay, ribavirin 12 (#196066, MP Biomedicals, Solon, OH), was solubilized at 8 mg/mL in DMSO (Sigma, St. Louis, MO). The stock solution was diluted to a final concentration of 164 μM in assay media (DMEM without phenol red, 1.5% bovine serum albumin [BSA], 4 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin; Gibco, Grand Island, NY) before each experiment and discarded afterwards. Final DMSO concentration in each well was 0.5%.
A collection of compounds selected for their conformance with the Lipinski rules 21 was purchased solubilized at 1 mg/mL in DMSO from ChemBridge Corporation (San Diego, CA). Before each experiment, all compounds were diluted to approximately 14 or 114 μM in assay media for the screen.
Influenza high-throughput screen
The high-throughput screen for the identification of potential inhibitors of the influenza virus has been described previously. 18 Briefly, MDCK cells (3 × 10 5 cells/mL) were dispensed into black, clear-bottom, 384-well plates at a density of 6000 cells/well in a 20-μL assay medium, using a WellMate (Matrix, Hudson, NH), and incubated 24 h at 37°C, 5% CO 2 , with high humidity. The next day, 5 μL of each compound was added to cells using a Biomek FX liquid handler (Beckman Coulter, Fullerton, CA). This resulted in a final drug concentration of 14 μM (0.5% DMSO) or 114 μM (<1% DMSO) for all samples. Within 30 min of compound addition, cells were infected with 5 μL of diluted virus at a concentration of 100 TCID 50 doses using a WellMate (multiplicity of infection [MOI] of 0.005 pfu/cell). Virus was diluted from amplified virus stock prepared in egg allantoic fluid into assay media containing 15 mg/mL of N-acetyl trypsin, for a final virus stock dilution of 1:10,000 and a final N-acetyl trypsin concentration of 2.5 μg/mL. Internal controls consisted of wells containing cells only, cells infected with virus, and virus-infected cells treated with ribavirin. Plates were incubated at 37°C, 5% CO 2 , for 72 h. After incubation, 30 μL of Cell Titer Glo (Promega, Madison, WI) was added to each well using a WellMate and incubated at room temperature (RT) for 10 to 30 min. Luminescence was measured using a Envision plate reader (PerkinElmer, Wellesley, MA).
Secondary confirmatory assays
For dose-response assays, compounds were diluted serially in serum-free media containing 0.5% DMSO final per well in a plate-to-plate matrix rather than in a well-to-well matrix. This allows 320 compounds in 1 plate to be diluted together, resulting in a 10-point dose-response dilution series. This method is referred to as a stacked plate. It can be visualized as a serial dilution series proceeding vertically through a stack of plates with the high-dose plate on top and the low-dose plate on the bottom (final plate well concentration ranging from 147 to 0.285 μM and a final DMSO concentration of ≤1%). Plate-to-plate variability was controlled by normalizing the compound data using in-plate controls. Cell-only values equal 100% inhibition of CPE, and virus values equal 0% inhibition. For compounds, the percent inhibition is calculated as follows: 100*(Cmpd Lum -Median Virus Ctrl)/(Median Cell Ctrl -Med Virus Ctrl). We control for positional variation during assay development and validation where methods are developed to minimize or eliminate positional artifacts such as edge effects.
Plaque assay
We developed a plaque assay to confirm the antiviral compound effect and determine the potency of "hit" compounds. This was accomplished by indirectly quantifying the amount of virus by staining for the presence of the influenza strain A/Udorn/72 Nprotein. Briefly, 1 mL of MDCK cells (3 × 10 5 cells/mL) was dispensed into 12-well plates and incubated 24 h at 37°C, 5% CO 2 , with high humidity. The next day, media were removed and cells were infected with 200 μL of 100 TCID 50 , which corresponds to an MOI of 0.005 pfu/cell for 1-h adsorption at 37°C. Media were replaced after infection with 1 mL of media containing compounds to a final compound concentration of 57 μM (0.5% DMSO), and plates were returned to 37°C. The infectious progeny virus produced in the supernatant was harvested after 48 h and measured with a low-viscosity-overlay plaque assay in conjunction with an immunostaining method. In brief, 50 μL from 10-fold serial dilutions of the supernatants was made in cell culture medium and was added to monolayers of MDCK cells in 96-well plates. The plates were incubated for 1 h at 37°C, and then 50 μL of the cell culture medium containing 2% of Avicel™ RC/CL (FMC Biopolymer, Princeton, NJ) was added into each well and returned to 37°C. Twenty-four hours later, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) and immunostained for viral N protein as described 20 but with some minor modifications. To detect the influenza Nprotein, we used a goat polyclonal antibody made against influenza A virus (strain H3N2; Virostat, Inc, Portland, ME) for the primary antibody and a peroxidase-labeled antigoat antibody for the secondary antibody; both were used at a dilution of 1 to 1000. The plaque was developed with the peroxidase substrate, True Blue™ (KPL, Gaithersburg, MD). Measurements were performed in triplicate for each dilution of sample tested.
Time of addition compound screen
MDCK cells were plated in 96-well black tissue culture plates at 15,000 cells per well in 100 μL and incubated 24 h at 37°C, 5% CO 2 . Lead candidate compounds were diluted in media to give a final concentration of 57 μM and added to plates at -1, 0, 3, 6, 12, and 24 h postinfection. Cells were infected with influenza A/Udorn/72 at an MOI of 0.1 and were incubated at 37°C, 5% CO 2 . After 72 h, 20 μL MTS was added, and plates were incubated an additional 2 h at 37°C, 5% CO 2 . Plates were read at an absorbance of 490 nm on an Envision plate reader. Ribavirin was used as a control compound at a final concentration of 82 μM.
Data analysis
Data were analyzed using ActivityBase software (IDBS, Inc, Guildford, UK). Percent CPE inhibition was defined as *100. The definition of *100 is that 100% inhibition of virus is equal to 100 times 1 minus the test compound minus the median of the virus divided by the median of the cell control minus the median of the virus (inhibition of virus = 100*[1 -(test compound -median virus)/(median cells -median virus)]). The cell viability is calculated separately in the dose-response assays.
Percent cell viability was defined as (test compound/cell control)*100. An active compound, or "hit," was defined as a compound that exhibited a %CPE inhibition of >50% without compromising cell viability. Ten concentrations of each drug were added to 384-well plates in triplicate to measure the effective concentration at which the drug inhibited cell death at 50% in the presence (EC 50 ) or absence of virus (IC 50 ), with the IC 50 defined as the cytotoxicity of the drug alone at 50%. The selective index (SI) was calculated as SI = IC 50 /EC 50 .
The Z factor values were calculated from 1 minus (3*standard deviation of cell control (σ c ) plus 3*standard deviation of the virus control (σ v )/[mean cell control signal (μ c ) minus mean virus control signal (μ v )]). 19 The signal/background (S/B) was calculated from mean cell control signal (μ c ) divided by the mean virus control signal (μ v ). The signal/noise (S/N) was calculated from the mean cell control signal (μ c ) minus the mean virus control signal (μ v ) divided by the (standard deviation of the cell control signal (σ c ) 2 minus the standard deviation of the virus control signal (σ v )) 1/2 .
RESULTS AND DISCUSSION
Compound screening results
In an effort to identify a palette of novel lead compounds acting through new mechanisms, we employed a high-throughput cell-based assay that measures the influenza virus-induced CPE in MDCK cells. 18 We screened a library of 100,000 compounds, which were selected for diversity and drug likeness using the Lipinski criteria for drug-like compounds. 21 A majority of this library of compounds, for example, had molecular weight ~350, CLogP value ~3.5, number of rotatable bonds ~4, topological polar surface area (tPSA) 22 ~60 Å 2 , hydrogen bond donors <3, and hydrogen bond acceptors <5, and they were devoid of compounds with reactive functional groups. The selected library
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contained a variety of heterocyclic compounds such as pyrroles, furans, thiophenes, indoles and their benzo analogs, isoindolines, imidazoles, pyrazoles, triazoles, isoxazoles, thiazoles, oxadiazoles, thiadiazoles, pyridines, quinolines, pyridazines, pyrimidines, pyrazines, quinazolines, quinoxalines, pyrrolidines, piperazines, and morpholines. The initial screening was performed in duplicate at a concentration of 14 μM (Fig. 1A) . We identified 22 compounds that showed >50% inhibition of the influenza virus strain A/Udorn/72 for a "hit" rate of 0.022%. The screen at 14 μM gave very few hits, and hence a subset of 16,000 compounds was run at a 114-μM (Fig. 1B) concentration to ascertain if our screening window lacked sensitivity for detection of hits. Indeed, we identified an additional 74 compounds that displayed >50% inhibition of the influenza virus for a hit rate of 0.46% in this pilot. This is an approximate 21-fold increase in the hit rate as compared with the screen at 14 μM (Fig. 1A) . Given the greater success, we screened the remaining 84,000 compounds at 114 μM with the recognition that our false-positive rate would likely increase in the primary screen. The additional screening activity resulted in an additional 307 hits. In total, we identified an additional 381 compounds that displayed >50% inhibition of CPE by the influenza virus for a hit rate of 0.38%. This was an approximate 17-fold increase in the hit rate as compared with screening at 14 μM. Four of the 381 compounds identified were previously discovered in the 14-μM screen: ARB-06-01916 (AACF-315846), ARB-06-067453 (AACF-372583), ARB-06-076399 (AACF-381531), and ARB-06-089154 (AACF-394288).
The hits were evaluated by measuring their antiviral activity, cell toxicity, and selectivity in dose-response experiments. We set our selective index (SI 50 ) as follows: <4, not active; SI 50 = 4-9, slightly active; SI = 10-49, moderately active; and SI 50 >50, highly active. Seven compounds were slightly active, 17 were moderately active, and 2 were highly active. The EC 50 curves of all the compounds, except for 2, never reached the 90% effective range due to the observed cellular toxicity of these compounds at higher concentrations. The inhibitory activities of selected compounds are shown in Table 1 and Figure 2 .
Among these compounds, 2-the bissulfonamide, ARB-06-076399, and the pyridothiazinone, ARB-06-089154-were chosen as interesting lead compounds on the basis of several considerations, including the fact that these 2 displayed at least a 3-log reduction from the control (pfu/mL) in a preliminary plaque reduction assay. A substructure search for analogs of these 2 compounds led to the identification of a total of 45 commercially available compounds as closely related analogs. Samples of these 45 compounds were procured and evaluated in dose-response and toxicity assays against the H3N2 virus. Two of these compounds were moderately active (SI 50 = 10-49). Interestingly, 2 of the compounds-the 1-benzoyl-3-arylthioureas, ARB-06-070333 (AACF-375463) and ARB-06-046310 (AACF-351438)-displayed SI 90 values of >3.7 and > 32.2, respectively (Table 1 and Fig. 2) . Overall, we observed a 0.4% hit rate for compounds that inhibited CPE by >40%, with an 8% confirmation of hits by dose response based on the criteria that a hit is confirmed if the compound has an SI 50 value of greater than 4.
We have developed a plaque reduction assay for the influenza virus in a 96-well format, which was used to screen 21 selected compounds from Table 1 as a confirmatory screen. The plaque reduction assays were performed in duplicate per compound. As shown in Figure 3 and Table 2 , 6 of these compounds (33%) exhibited a 2-log reduction or >100-fold difference from the control in pfu/mL. These compounds are the carboxanilides ARB-06-003174 (AACF-308027) and ARB-06-011087 (AACF-316018), the 1-benzoyl-3-arylthioureas ARB-06-047279 (AACF-352407) and ARB-06-100378 (AACF-405513), the pyridothiazinone ARB-06-089154 (AACF-394288), and the sulfonamides ARB-06-018302 (AACF-323316) and ARB-06-076399 (AACF-381531).
Finally, we employed an assay to determine the point in the influenza virus life cycle that the dose-response and plaque assay hits inhibited. This screen allowed us to ascertain if the inhibition activity of the compound was early (entry) or late (replication) in the virus life cycle. In this screen, compounds were added in triplicate to plates at time points -1, 0, 3, 6, 12, and 24 h postinfection (Fig. 4) . Four of these 7 compounds-ARB-06-003174 The aim of this study was to discover new potential influenza antiviral lead compounds using our high-throughput cell-based assay as the primary screen. In addition, we compared the effectiveness at a low (14 μM) and high concentration (114 μM) of compound. Of the total number of compounds screened in dose response and cell toxicity, only 26 compounds met our criteria of activity: the efficacy EC 50 value of <25 μM and with toxicity to efficacy SI 50 of >10. We performed SAR analysis of each of these hits to identify and choose the most promising lead compounds. We selected 21 compounds for further analysis. In the plaque reduction assay, we identified 6 compounds that exhibited a 2-log reduction or >100-fold difference from the control in pfu/mL. These compounds are grouped by structural class and the structures given in Figure 5 . In view of these data, we believe that the design, synthesis, and evaluation of targeted analogs of these various scaffolds in an iterative fashion should lead us toward the identification of compounds possessing greatly improved potency and selectivity that can be developed into clinically useful therapeutic agents.
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FIG. 4.
Time of addition compound screen against influenza A/Udorn/72 (H3N2). Madin Darby canine kidney (MDCK) cells were plated in 96-well black tissue plates at 15,000 cells per well and incubated 24 h at 37°C, 5% CO 2 . Test compounds were diluted in media to give a final concentration of 57 μM and added to plates at time points -1, 0, 3, 6, 12, and 24 h postinfection. Cells were infected with influenza A/Udorn/72 at a multiplicity of infection (MOI) of 0.1 and incubated 72 h at 37°C, 5% CO 2 . MTS was added and plates were incubated for an additional 2 h at 37°C, 5% CO 2 . The plates were read at an absorbance of 490 nm on an Envision plate reader. Ribavirin was used as a control compound.
